Market Closed -
Nasdaq
04:00:00 2024-07-09 pm EDT
|
5-day change
|
1st Jan Change
|
0.8299
USD
|
-0.71%
|
|
+7.31%
|
-74.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
198.4
|
146.5
|
218.6
|
131.1
|
227.6
|
58.88
|
-
|
-
|
Enterprise Value (EV)
1 |
198.4
|
146.5
|
218.6
|
131.1
|
227.6
|
58.88
|
58.88
|
58.88
|
P/E ratio
|
-2.69
x
|
-1.66
x
|
1.82
x
|
-2.42
x
|
-4.35
x
|
-1.02
x
|
-1.77
x
|
-1.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
11.6
x
|
1.05
x
|
87.2
x
|
581
x
|
215
x
|
1.56
x
|
8.53
x
|
EV / Revenue
|
-
|
11.6
x
|
1.05
x
|
87.2
x
|
581
x
|
215
x
|
1.56
x
|
8.53
x
|
EV / EBITDA
|
-
|
-
|
1.76
x
|
-2.38
x
|
-3.95
x
|
-0.85
x
|
-0.92
x
|
-1
x
|
EV / FCF
|
-3.88
x
|
-
|
-
|
-
|
-
|
-0.73
x
|
-0.79
x
|
-0.71
x
|
FCF Yield
|
-25.8%
|
-
|
-
|
-
|
-
|
-136%
|
-126%
|
-140%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
47,816
|
63,435
|
68,092
|
70,467
|
70,681
|
70,945
|
-
|
-
|
Reference price
2 |
4.150
|
2.310
|
3.210
|
1.860
|
3.220
|
0.8299
|
0.8299
|
0.8299
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
12.62
|
208.4
|
1.503
|
0.3917
|
0.2742
|
37.67
|
6.9
|
EBITDA
1 |
-
|
-
|
124.4
|
-55.04
|
-57.68
|
-69.38
|
-64.05
|
-58.97
|
EBIT
1 |
-61.41
|
-81.43
|
149.2
|
-55.55
|
-59.28
|
-67.67
|
-45.98
|
-60.39
|
Operating Margin
|
-
|
-645.4%
|
71.58%
|
-3,696.43%
|
-15,134.4%
|
-24,676.6%
|
-122.05%
|
-875.17%
|
Earnings before Tax (EBT)
1 |
-60.46
|
-81.04
|
124.2
|
-54.17
|
-52.34
|
-58.04
|
-38.55
|
-54.9
|
Net income
1 |
-60.46
|
-81.04
|
122.8
|
-54.17
|
-52.34
|
-60.12
|
-45.06
|
-63.26
|
Net margin
|
-
|
-642.26%
|
58.95%
|
-3,604.66%
|
-13,362%
|
-21,923.09%
|
-119.6%
|
-916.87%
|
EPS
2 |
-1.540
|
-1.390
|
1.760
|
-0.7700
|
-0.7400
|
-0.8150
|
-0.4683
|
-0.5700
|
Free Cash Flow
1 |
-51.15
|
-
|
-
|
-
|
-
|
-80.32
|
-74.35
|
-82.45
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-29,289.26%
|
-197.36%
|
-1,194.9%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
1.445
|
-
|
0.0111
|
0.0463
|
0.0662
|
0.075
|
0.109
|
0.1416
|
0.148
|
0.0529
|
0.0572
|
0.0616
|
0.0667
|
0.0667
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-17.79
|
-17.28
|
-17.49
|
-17.45
|
-17.42
|
-
|
-
|
EBIT
1 |
-11.65
|
-14.29
|
-14.3
|
-12.8
|
-12.17
|
-14.89
|
-14.17
|
-12.03
|
-18.19
|
-17.42
|
-17.17
|
-17.34
|
-15.74
|
-13.47
|
-13.65
|
Operating Margin
|
-
|
-988.59%
|
-
|
-115,350.09%
|
-26,302.29%
|
-22,509.52%
|
-18,895.97%
|
-11,038.66%
|
-12,848.51%
|
-11,768.24%
|
-32,477.48%
|
-30,282.36%
|
-25,547.79%
|
-20,208.49%
|
-20,478.48%
|
Earnings before Tax (EBT)
1 |
-26.35
|
-16.06
|
-14.59
|
-11.97
|
-11.5
|
-13.36
|
-12.41
|
-11.25
|
-15.32
|
-11.69
|
-15.27
|
-15.57
|
-13.88
|
-11.44
|
-11.59
|
Net income
1 |
-26
|
-16.11
|
-14.59
|
-11.97
|
-11.5
|
-13.36
|
-12.41
|
-11.25
|
-15.32
|
-11.69
|
-15.67
|
-15.98
|
-14.54
|
-11.44
|
-11.59
|
Net margin
|
-
|
-1,114.46%
|
-
|
-107,817.75%
|
-24,858.64%
|
-20,187.74%
|
-16,544.44%
|
-10,326.14%
|
-10,823.71%
|
-7,901.35%
|
-29,631.96%
|
-27,910.04%
|
-23,588.53%
|
-17,153.14%
|
-17,378.13%
|
EPS
2 |
-0.3800
|
-0.2300
|
-0.2100
|
-0.1700
|
-0.1600
|
-0.1900
|
-0.1800
|
-0.1600
|
-0.2200
|
-0.1700
|
-0.2188
|
-0.2312
|
-0.1850
|
-0.1600
|
-0.0700
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/13/23
|
5/5/23
|
8/4/23
|
11/3/23
|
3/8/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-51.1
|
-
|
-
|
-
|
-
|
-80.3
|
-74.4
|
-82.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
110%
|
-34.7%
|
-47.6%
|
-107%
|
-284%
|
-134%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.06
|
-
|
-
|
-
|
0.14
|
0.02
|
0.12
|
0.18
|
Capex / Sales
|
-
|
-
|
-
|
-
|
35.09%
|
7.66%
|
0.31%
|
2.55%
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Last Close Price
0.8299
USD Average target price
3.314
USD Spread / Average Target +299.36% Consensus |
1st Jan change
|
Capi.
|
---|
| -74.23% | 59.3M | | +19.44% | 124B | | +20.01% | 114B | | +21.11% | 25.83B | | -23.72% | 19.42B | | -18.17% | 16.2B | | -19.87% | 15.31B | | +55.81% | 14.32B | | +8.76% | 14.31B | | -48.79% | 14.19B |
Bio Therapeutic Drugs
|